Neurorehabilitation News

Halozyme Therapeutics announced that argenx received FDA approval for Vyvgart Hytrulo with Enhanze for subcutaneous use in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

AUSTIN, Texas — Venous manometry and neuroimaging may provide additional value when diagnosing patients who do not meet criteria for idiopathic intracranial hypertension, according to a poster presented here.

The FDA has granted orphan drug designation to DTx-1252, an investigational small interfering RNA therapeutic to treat Charcot-Marie-Tooth disease type 1A.

MIAMI BEACH, Fla. — Treatment with ketamine may be an effective augmenter of risk mitigation for suicidality and effective modulator for suicide-related cognitive processing in adults, according to data presented here.

The American Academy of Neurology has submitted a formal national coverage determination reconsideration request to CMS regarding current coverage of amyloid-targeting monoclonal antibodies for Alzheimer’s disease, including Leqembi.

The FDA has granted 510(k) clearance to Neuronetics Inc. for its obsessive-compulsive disorder motor threshold cap technology for NeuroStar Advanced Therapy for Mental Health.

Apellis Pharmaceuticals Inc. announced that its phase 2 MERIDIAN study investigating systemic pegcetacoplan as a treatment for ALS failed to meet efficacy measures of overall function, survival, lung function and muscle strength.

The FDA has granted conditional use with MRI to an implantable transvenous phrenic nerve stimulation therapy for adults with moderate to severe central sleep apnea.

BOSTON — The BrainPath device successfully surgically evacuated intracerebral hemorrhages in most patients enrolled in the ENRICH trial, Andrew Russman, DO, said in a Healio video during the American Academy of Neurology Annual Meeting.

Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to research in The Lancet Neurology.